Menu
Search
|

Menu

Close
X

Abiomed Inc ABMD.OQ (NASDAQ Stock Exchange Global Select Market)

268.45 USD
+4.48 (+1.70%)
As of Feb 23
chart
Previous Close 263.97
Open 265.01
Volume 168,883
3m Avg Volume 134,898
Today’s High 268.57
Today’s Low 261.61
52 Week High 273.56
52 Week Low 114.53
Shares Outstanding (mil) 44.22
Market Capitalization (mil) 11,869.82
Forward P/E 109.10
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.70 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
419
FY17
445
FY16
330
FY15
230
EPS (USD)
FY18
2.128
FY17
1.162
FY16
0.850
FY15
2.571
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
109.10
33.62
Price to Sales (TTM)
vs sector
21.82
8.35
Price to Book (MRQ)
vs sector
18.79
5.22
Price to Cash Flow (TTM)
vs sector
97.26
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
20.66
13.63
Return on Equity (TTM)
vs sector
21.38
15.39

EXECUTIVE LEADERSHIP

Michael Minogue
Chairman of the Board, President, Chief Executive Officer, Since 2005
Salary: $648,748.00
Bonus: --
Ian McLeod
Principal Financial Officer, Principal Accounting Officer, Vice President, Controller, Since 2017
Salary: --
Bonus: --
David Weber
Chief Operating Officer, Since 2007
Salary: $382,616.00
Bonus: --
William Bolt
Senior Vice President, Global Quality, Regulatory and Clinical Operations, Since 2015
Salary: $330,855.00
Bonus: --
Andrew Greenfield
Vice President, General Manager - Global Marketing, Since 2014
Salary: $211,592.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

22 CHERRY HILL DR
DANVERS   MA   01923-2575

Phone: +1978.7775410

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

SPONSORED STORIES